.svg "CAMZYOS®V (mavacamten)")
This information is intended for members of the public in the UK only.
Information on CAMZYOS® (mavacamten) for members of the public
This section contains reference information only. Bristol Myers Squibb is unable to provide advice on personal medical matters. Please contact your doctor or other relevant healthcare professional for specific, health-related advice and support.
CAMZYOS contains the active substance mavacamten, which is a type of drug known as a cardiac myosin inhibitor. CAMZYOS is used to treat adults with a type of heart condition called obstructive hypertrophic cardiomyopathy and this medicine works by reducing excess contraction of the heart and the obstruction to blood flow to the body.
The CAMZYOS (mavacamten) Summary of Product Characteristics and Patient Information Leaflet can be found on the electronic medicines compendium (emc).
Report possible side effects (patients and members of the public in the UK)
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly.
UK - see www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects.
